@FierceMedDev: Boston Scientific buying Bard's electrophysiology biz for $275M. News | Follow @FierceMedDev
@DamianFierce: For CROs big and small, you're only as good as your reputation. The view from DIA 2013: Feature | Follow @DamianFierce
@MichaelGFierce: SEC hammers imaging company, CEO with fraud charges. Story | Follow @MichaelGFierce
> Despite mounting pressure from investors to restructure, Alere ($ALR) is sticking to its guns, filing proxy materials and reaffirming its board nominations. More
> After being held hostage for almost a week by workers at his company's Chinese plant, Specialty Medical Supplies executive Chip Starnes has paid a ransom and returned home. Story
> Zoll Medical's GPS-like CPR technology helped paramedics nearly double survival rates from out-of-hospital cardiac arrest. News
> Rexam is looking to sell off its healthcare business, which makes inhalers and other medical devices, for up to $1.2 billion. Article
> French diagnostics outfit bioMérieux won a CE mark for its third-generation immunoassay platform. Item
Biotech News
@FierceBiotech: ICYMI yesterday: J&J's pharma chairman lands 'more deals' in Boston innovation push. News | Follow @FierceBiotech
@JohnCFierce: Where are the FDA approvals on biosims? EMA backs two Remicade knockoffs. Release | Follow @JohnCFierce
@RyanMFierce: Big week for Prosensa. Priced $78M IPO on the heels of breakthrough status for lead DMD Rx partnered w/ GSK. PR | More | Follow @RyanMFierce
> Lab animal wars: Scientists blast living conditions of stolen mouse models. Story
> Buyout buzz: Royalty might mount joint effort to acquire Elan. Article
> Resverlogix stock craters on failure of cardio drug trial. Report
Pharma News
@FiercePharma: Finally… EMA's press release about this week's drug moves: Release | Follow @FiercePharma
@EricPFierce: There is a connection between the separate deals Aspen has announced with MSD and GSK. It is heparin. More | Follow @EricPFierce
@CarlyHFierce: There are billions of dollars to be saved on healthcare spending via adherence... but how? Story | Follow @CarlyHFierce
> FDA sends J&J CRL on Xarelto for stent thrombosis. Article
> Dendreon's Provenge gets recommendation in Europe. More
> Pfizer returns to buyback strategy to appease shareholders. Report